News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fosun Pharma (2196) In-Licenses Female Sexual Desire Disorder Drug In $106 Million Deal



9/13/2017 9:58:24 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Shanghai Fosun Pharma signed a $106 million agreement for greater China rights to a female sexual desire disorder treatment from Palatin of the US. Fosun will be in charge of regulatory approval and marketing of bremelanotide in its territories. Palatin has completed two successful Phase III trials of bremelanotide in the US and will file for FDA approval in early 2018. Fosun will pay $5 million upfront and another $7.5 million upon China approval. It will also be liable for up to $92.5 in sales milestones.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES